Table 3.
In vivo antitumor activity of DBDFT against mice S180 and H22 (
±SD).
| Cells | Dosage (mg kg−1) | Mice weight (g) | Average tumor weight (g) | Inhibition (%) | p |
| Initial/Final (10 days) | |||||
| S180 | 0.0 | 23.29±1.28/27.62±3.66 | 2.39±0.64 | – | – |
| 2.5 | 23.19±0.91/27.65±1.51 | 1.88±0.16 | 21.04* | <0.05 | |
| 5.0 | 23.29±1.15/26.66±2.02 | 1.59±0.44 | 33.36** | <0.01 | |
| 10.0 | 23.33±1.47/25.27±2.02 | 0.87±0.27 | 63.62** | <0.01 | |
| 2.5 (Positive DDP) | 23.36±1.14/21.19±1.93 | 0.52±0.24 | 78.24** | <0.01 | |
| H22 | 0.0 | 23.03±0.82/28.04±2.93 | 2.12±0.50 | – | – |
| 2.5 | 23.20±0.73/27.70±3.95 | 2.02±0.34 | 4.53 | – | |
| 5.0 | 23.42±0.67/26.98±4.00 | 1.57±0.35 | 25.19* | <0.05 | |
| 10.0 | 23.12±0.72/25.04±2.67 | 1.02±0.16 | 52.05** | <0.01 | |
| 2.5 (Positive DDP) | 23.23±1.59/20.16±1.41 | 0.58±0.39 | 79.15** | <0.01 |
Note: Mice number for the starting and final test was 10. The dosage of each sample were 0.0 mg kg−1 (normal group), 2.5 mg kg−1 (Low dosage group), 5 mg kg−1 (Middle dosage group), 10 mg kg−1 (High dosage group), respectively. Positive DDP group was that with cisplatin as positive contrast drug. The SD values were obtained in ten independent experiments.
*p<0.05,
**p<0.01.